Lakewood-Amedex Biotherapeutics, Inc. Quality Score
LABT
Weak across most dimensions. This doesn't mean avoid, but the burden of proof is on the bull case.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Negative FCF, no valuation support
FCF negative, burning cash after capex
Business Quality & Capital Allocation
Positive debt with no FCF to service it
Below 8%, may not cover cost of capital
Lakewood-Amedex Biotherapeutics (LABT) quality: score, margins and returns
Lakewood-Amedex Biotherapeutics (LABT) scores 0/100 on Intrinsiqq's quality score (a lower-quality business), a weighted blend of 3 metrics each scored 0 to 100 and -254.4% ROIC. Every metric is computed from company filings; this is analysis, not investment advice.
Frequently asked
Is Lakewood-Amedex Biotherapeutics (LABT) a high-quality business?+
Lakewood-Amedex Biotherapeutics scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 3 metrics each scored 0 to 100, which rates it a lower-quality business on these measures. Recent figures include a -254.4% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Lakewood-Amedex Biotherapeutics's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from LABT's company filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Lakewood-Amedex Biotherapeutics scores well and where it falls behind.
What is Lakewood-Amedex Biotherapeutics's return on invested capital (ROIC)?+
Lakewood-Amedex Biotherapeutics earns about -254.4% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to LABT's margins and growth on this scorecard to judge durability.
Peers
Biotechnology · Pick stocks to compare with LABT
Spot a number that looks wrong?
Download this analysis as a PDF (Pro)
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LABT
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.